Dyax Corp. (NASDAQ:DYAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications.

Recs

0
Player Avatar fatcanibal (34.12) Submitted: 6/14/2007 4:17:27 PM : Outperform Start Price: $4.55 DYAX Score: -53.22

Well organized and focused

Featured Broker Partners


Advertisement